Genmab — Maj 2021

[Bulder]

Just a moment...

(www.onclive.com)

[GeorgeBest]

If you only look at patients receiving optimal dose of Epcoritamab (48 mg), isn’t the Epcoritamab data better then?

[Bulder]

Maybritt a little. But is it enough to be meaningfull?

[Bulder]

NBI opfører sig da noget pænere end øvrige us-inden.

[Bulder]

Inden

[Bulder]

Index

[Bulder]

Forpulede iPad

[Bulder]

... relativt

[Bulder]

Ipad er absolut forpulet. NBI er relativt velopdragen i dag.

[Bulder]

Jeg tror jeg fandt ud af at slå automatiske rettelser fra.

[Bulder]

Ret voldsomt ellers i us her i aften. De næste to dage bliver spændende. Hvis det fortsætter, så bliver det ikke morsomt på mandag.

[Bulder]

Den ene fed’er efter den anden er ude at slå koldt vand i blodet. Håber det trænger ind.

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Spørgsmål til Q&A er meget savnet.

[E_L]

@Bulder , If I look at comparison with earlier epcoritamab data, for the higher dose;

[E_L]

For DLBCL ≥48 mg (n=11); ORR 91% (CR=55%; PR=36%) versus november data: (n=7); ORR 100% (CR=28.6%; PR=71.4%)

[E_L]

FL at doses ≥12 mg (n=5) was 80% (CR=60%; PR=20%) versus november data: (n=3); ORR 100% (CR=66.7%; PR=33.3%)

[E_L]

I think that looks very very solid, with responses clearly deepening over time, PR’s converting to CR’s. No additional Aes. That treatment was ongoing in only 15 (22%) patients from the starting of the original 68 is unpleasant to read though, but this is in aggressive disease with patients heavily pretreated.

[E_L]

I find the comparisson with Glofitamab a bit difficult, they are longer into the trial (27 months? vs 14 months). If i can compare Glofi DLBCL ORR of 41.1% (n = 30), with CR in 28.8% (n = 21). And FL ORR 55.2% and CR 34.5%, Epco clearly seems better?

[E_L]

It is rather annoying that EHA have embargoed some abstracts again, I copied this on Talquetamab yesterday: